Condition: Bone Cancer Metastatic · Radiofrequency Ablation · Spine Metastases · Sponsor: National and Kapodistrian University of Athens
This pilot study will try to demonstrate metabolic changes in spine lesions treated by Augmentation and Ablation, according to existing standards of practice. Our purpose is to show the efficacy of a new radiofrequency ablation (RFA) in combination with augmentation, using a percutaneous ablation device (Osteocool-Medtronic) in the treatment of secondary vertebral bone tumor, avoiding concurrent bias related to other treatments of the disease.
This description comes directly from the study's public registry record.
Alexis Kelekis, MD PHD, EBIR · +302105831806 · akelekis@med.uoa.gr
MARIA IOANNIDI, MD
Always discuss trial participation with your own doctor first.
| 3rd Department of Radiology, NKUOA, General Hospital "LAIKON" | Athens, Athens, Greece | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06716294